| Name | Title | Contact Details |
|---|
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.
Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing
Cerevance is advancing a promising pipeline of new treatments for central nervous system diseases.
itsRX is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Dunn Group is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.